Dancann Pharma A/S reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was DKK 2.8 million compared to DKK 1.1 million a year ago. Net loss was DKK 3.02 million compared to DKK 4.64 million a year ago. Basic loss per share from continuing operations was DKK 0.05.
For the six months, sales was DKK 3.48 million compared to DKK 2.74 million a year ago. Net loss was DKK 6.55 million compared to DKK 7.82 million a year ago. Basic loss per share from continuing operations was DKK 0.08.